Biotech Appreciation Then Decline

I just completed a regression analysis of the over 50 biotechnology parcels that I have purchased over the past several years. In 94% of all cases, every parcel appreciated prior to news of trial results, etc. being reported to the market place. In addition, 67% declined after news was reported (either positive or negative trial results). As I and Gassy have stated on numerous occasions, Innate is not trading any where near where it should be at this time prior to trial results. We have seen a steady decline in parcel pricing from around A$.76/share to A$.63/share (20% decline in less than 2 weeks). I challenge anyone here to convince me that this is not bad news coming. It appears that we may have been taken to the pond on this one!